Owners, management and financials
CVR: 32323502
Previous names: ACP 30.06.2012 1 A/S
EUR 5,567,000
Gross profit
Net result: EUR -5,238,000
ASCENDIS PHARMA A/S (100%)
CVR · view owners
Jan Møller Mikkelsen
Board: Michael Wolff Jensen (chair) and 2 members
CVR · view management
Active
Founded 29 June 2012
CVR · view overview
0 employees
Annual report 2025 · average
Name registered: ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S
CVR · 30/01/2013
View the full event history
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.
Source: annual report 2025, Danish Business Authority
The financial health of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S shows significant volatility, with a concerning trend of declining profitability and negative equity. In 2025, the company reported a gross profit of €5.57 million but incurred a loss of €5.24 million, following a substantial loss of €44.49 million in 2023. Equity has deteriorated from €14.81 million in 2021 to -€38.64 million in 2025, indicating increasing financial distress. The absence of revenue disclosures raises concerns about the company's ability to generate sustainable income, while the fluctuating gross profit margins suggest operational challenges within the pharmaceutical manufacturing sector. Overall, the company faces significant risks that could impact its position in the industry.
AI-generated summary · Generated 13/08/2026
Selskabets formål er at udvikle ideer og præparater til sygdomsbekæmpelse ad medicinsk vej, at producere og sælge sådanne præparater eller ideer, at eje aktier i selskaber med samme formål samt at udøve virksomhed, som står i naturlig forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 5.6 mio. EUR | -5.2 mio. EUR | 9.2 mio. EUR | -38.6 mio. EUR | 0 | |
| 202401/01/2024 – 31/12/2024 | 22.1 mio. EUR | 5 mio. EUR | 13.7 mio. EUR | -31.9 mio. EUR | 0 | |
| 202301/01/2023 – 31/12/2023 | -44.6 mio. EUR | -44.5 mio. EUR | 8 t. EUR | -37.8 mio. EUR | 0 | |
| 202201/01/2022 – 31/12/2022 | -8.3 mio. EUR | -8.1 mio. EUR | 6.7 mio. EUR | 6.7 mio. EUR | 0 | |
| 202101/01/2021 – 31/12/2021 | -6 t. EUR | 213 t. EUR | 14.8 mio. EUR | 14.8 mio. EUR | 0 | |
| 202001/01/2020 – 31/12/2020 | -30 t. EUR | 197 t. EUR | 14.6 mio. EUR | 14.6 mio. EUR | 0 | |
| 201901/01/2019 – 31/12/2019 | -2 t. EUR | 210 t. EUR | 14.4 mio. EUR | 14.4 mio. EUR | 0 | |
| 201801/01/2018 – 31/12/2018 | 7 t. EUR | 371 t. EUR | 14.2 mio. EUR | 14.2 mio. EUR | 0 | |
| 201701/01/2017 – 31/12/2017 | 257 t. EUR | -480 t. EUR | 13.8 mio. EUR | 13.8 mio. EUR | 0 | |
| 201601/01/2016 – 31/12/2016 | 3.2 mio. EUR | 3.4 mio. EUR | 14.4 mio. EUR | 14.3 mio. EUR | - | |
| 201501/01/2015 – 31/12/2015 | 5.4 mio. EUR | 5.6 mio. EUR | 13.9 mio. EUR | 10.9 mio. EUR | - | |
| 201401/01/2014 – 31/12/2014 | 5.5 mio. EUR | 5.8 mio. EUR | 13.2 mio. EUR | 5.3 mio. EUR | - | |
| 201301/01/2013 – 31/12/2013 | 18.5 mio. | 16.3 mio. | 116 mio. | 19.1 mio. | - |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is 32323502.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is owned by ASCENDIS PHARMA A/S.
The management of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S consists of Jan Møller Mikkelsen.
The board of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S consists of Michael Wolff Jensen, Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen, with Michael Wolff Jensen as chair.
In 2025, ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S reported a gross profit of EUR 5,567,000.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S had an average of 0 employees in the 2025 financial year according to the annual report.
Claim this page to add your logo and social links. Free to get started.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2025. Gross profit came to DKK 5,567,000, and the net result was DKK -5,238,000.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2024. Gross profit came to DKK 22,097,000, and the net result was DKK 5,001,000.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2023. Gross profit came to DKK -44,610,517, and the net result was DKK -44,491,101.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2022. Gross profit came to DKK -8,328,991, and the net result was DKK -8,089,721.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2021. Gross profit came to DKK -6,046, and the net result was DKK 213,018.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2020. Gross profit came to DKK -30,400, and the net result was DKK 196,963.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2019. Gross profit came to DKK -1,850, and the net result was DKK 210,420.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2018. Gross profit came to DKK 7,218, and the net result was DKK 371,171.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2017. Gross profit came to DKK 257,277, and the net result was DKK -479,755.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2016. Gross profit came to DKK 3,244,713, and the net result was DKK 3,444,680.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2015. Gross profit came to DKK 5,370,361, and the net result was DKK 5,606,878.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2014. Gross profit came to DKK 5,456,890, and the net result was DKK 5,786,449.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2013. Gross profit came to DKK 18,483,731, and the net result was DKK 16,254,792.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its interim report for the period June 29, 2012 – December 31, 2012.
On January 30, 2013, the company changed its name from ACP 30.06.2012 1 A/S to ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S.
As of June 29, 2012, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S.
As of June 29, 2012, Michael Wolff Jensen has joined the board of directors of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S.
As of June 29, 2012, Jan Møller Mikkelsen has joined the board of directors of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S.
As of June 29, 2012, Anni Lotte Kirstine Pedersen has joined the board of directors of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S.
As of June 29, 2012, Jan Møller Mikkelsen is registered as adm. dir. of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S.
As of June 29, 2012, ASCENDIS PHARMA A/S is registered as an owner of ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S with an ownership share of 100%.
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S was founded on June 29, 2012.
Companies in the same industry and area
CVR 29918791
CVR 32323537
CVR 37011185
CVR 46029518
CVR 41101970
